Copyright Reports & Markets. All rights reserved.

Global Psychiatric API Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Psychiatric API Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Venlafaxine
    • 1.3.3 Duloxetine
    • 1.3.4 Olanzapine
    • 1.3.5 Paroxetine
    • 1.3.6 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Psychiatric API Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Major Depressive Disorder
    • 1.4.3 Generalized Anxiety Disorder
    • 1.4.4 Fibromyalgia
    • 1.4.5 Schizophrenia
    • 1.4.6 Others
  • 1.5 Global Psychiatric API Market Size & Forecast
    • 1.5.1 Global Psychiatric API Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Psychiatric API Sales Quantity (2021-2032)
    • 1.5.3 Global Psychiatric API Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Psychiatric API Product and Services
    • 2.1.4 Pfizer Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 Eli Lilly
    • 2.2.1 Eli Lilly Details
    • 2.2.2 Eli Lilly Major Business
    • 2.2.3 Eli Lilly Psychiatric API Product and Services
    • 2.2.4 Eli Lilly Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Eli Lilly Recent Developments/Updates
  • 2.3 Salutas Pharma
    • 2.3.1 Salutas Pharma Details
    • 2.3.2 Salutas Pharma Major Business
    • 2.3.3 Salutas Pharma Psychiatric API Product and Services
    • 2.3.4 Salutas Pharma Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Salutas Pharma Recent Developments/Updates
  • 2.4 Bora Pharmaceutical
    • 2.4.1 Bora Pharmaceutical Details
    • 2.4.2 Bora Pharmaceutical Major Business
    • 2.4.3 Bora Pharmaceutical Psychiatric API Product and Services
    • 2.4.4 Bora Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Bora Pharmaceutical Recent Developments/Updates
  • 2.5 Dr.Reddy's Laboratories
    • 2.5.1 Dr.Reddy's Laboratories Details
    • 2.5.2 Dr.Reddy's Laboratories Major Business
    • 2.5.3 Dr.Reddy's Laboratories Psychiatric API Product and Services
    • 2.5.4 Dr.Reddy's Laboratories Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Dr.Reddy's Laboratories Recent Developments/Updates
  • 2.6 Germany Pharmaceutical
    • 2.6.1 Germany Pharmaceutical Details
    • 2.6.2 Germany Pharmaceutical Major Business
    • 2.6.3 Germany Pharmaceutical Psychiatric API Product and Services
    • 2.6.4 Germany Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Germany Pharmaceutical Recent Developments/Updates
  • 2.7 Hengrui Pharmaceuticals
    • 2.7.1 Hengrui Pharmaceuticals Details
    • 2.7.2 Hengrui Pharmaceuticals Major Business
    • 2.7.3 Hengrui Pharmaceuticals Psychiatric API Product and Services
    • 2.7.4 Hengrui Pharmaceuticals Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Hengrui Pharmaceuticals Recent Developments/Updates
  • 2.8 Herui Pharmaceutical
    • 2.8.1 Herui Pharmaceutical Details
    • 2.8.2 Herui Pharmaceutical Major Business
    • 2.8.3 Herui Pharmaceutical Psychiatric API Product and Services
    • 2.8.4 Herui Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Herui Pharmaceutical Recent Developments/Updates
  • 2.9 Ren An Pharmaceutical
    • 2.9.1 Ren An Pharmaceutical Details
    • 2.9.2 Ren An Pharmaceutical Major Business
    • 2.9.3 Ren An Pharmaceutical Psychiatric API Product and Services
    • 2.9.4 Ren An Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Ren An Pharmaceutical Recent Developments/Updates
  • 2.10 Yaopharma
    • 2.10.1 Yaopharma Details
    • 2.10.2 Yaopharma Major Business
    • 2.10.3 Yaopharma Psychiatric API Product and Services
    • 2.10.4 Yaopharma Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Yaopharma Recent Developments/Updates
  • 2.11 Kanghong Pharmaceutical
    • 2.11.1 Kanghong Pharmaceutical Details
    • 2.11.2 Kanghong Pharmaceutical Major Business
    • 2.11.3 Kanghong Pharmaceutical Psychiatric API Product and Services
    • 2.11.4 Kanghong Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Kanghong Pharmaceutical Recent Developments/Updates
  • 2.12 Brilliant Pharmaceutical
    • 2.12.1 Brilliant Pharmaceutical Details
    • 2.12.2 Brilliant Pharmaceutical Major Business
    • 2.12.3 Brilliant Pharmaceutical Psychiatric API Product and Services
    • 2.12.4 Brilliant Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Brilliant Pharmaceutical Recent Developments/Updates
  • 2.13 Dongting Pharmaceutical
    • 2.13.1 Dongting Pharmaceutical Details
    • 2.13.2 Dongting Pharmaceutical Major Business
    • 2.13.3 Dongting Pharmaceutical Psychiatric API Product and Services
    • 2.13.4 Dongting Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Dongting Pharmaceutical Recent Developments/Updates
  • 2.14 Sichuan Chuanda West China Pharmaceutical
    • 2.14.1 Sichuan Chuanda West China Pharmaceutical Details
    • 2.14.2 Sichuan Chuanda West China Pharmaceutical Major Business
    • 2.14.3 Sichuan Chuanda West China Pharmaceutical Psychiatric API Product and Services
    • 2.14.4 Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Sichuan Chuanda West China Pharmaceutical Recent Developments/Updates
  • 2.15 Yangtze River Pharmaceutical
    • 2.15.1 Yangtze River Pharmaceutical Details
    • 2.15.2 Yangtze River Pharmaceutical Major Business
    • 2.15.3 Yangtze River Pharmaceutical Psychiatric API Product and Services
    • 2.15.4 Yangtze River Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Yangtze River Pharmaceutical Recent Developments/Updates
  • 2.16 Huahai Pharmaceutical
    • 2.16.1 Huahai Pharmaceutical Details
    • 2.16.2 Huahai Pharmaceutical Major Business
    • 2.16.3 Huahai Pharmaceutical Psychiatric API Product and Services
    • 2.16.4 Huahai Pharmaceutical Psychiatric API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Huahai Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Psychiatric API by Manufacturer

  • 3.1 Global Psychiatric API Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Psychiatric API Revenue by Manufacturer (2021-2026)
  • 3.3 Global Psychiatric API Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Psychiatric API by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Psychiatric API Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Psychiatric API Manufacturer Market Share in 2025
  • 3.5 Psychiatric API Market: Overall Company Footprint Analysis
    • 3.5.1 Psychiatric API Market: Region Footprint
    • 3.5.2 Psychiatric API Market: Company Product Type Footprint
    • 3.5.3 Psychiatric API Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Psychiatric API Market Size by Region
    • 4.1.1 Global Psychiatric API Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Psychiatric API Consumption Value by Region (2021-2032)
    • 4.1.3 Global Psychiatric API Average Price by Region (2021-2032)
  • 4.2 North America Psychiatric API Consumption Value (2021-2032)
  • 4.3 Europe Psychiatric API Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Psychiatric API Consumption Value (2021-2032)
  • 4.5 South America Psychiatric API Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Psychiatric API Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Psychiatric API Sales Quantity by Type (2021-2032)
  • 5.2 Global Psychiatric API Consumption Value by Type (2021-2032)
  • 5.3 Global Psychiatric API Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Psychiatric API Sales Quantity by Application (2021-2032)
  • 6.2 Global Psychiatric API Consumption Value by Application (2021-2032)
  • 6.3 Global Psychiatric API Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Psychiatric API Sales Quantity by Type (2021-2032)
  • 7.2 North America Psychiatric API Sales Quantity by Application (2021-2032)
  • 7.3 North America Psychiatric API Market Size by Country
    • 7.3.1 North America Psychiatric API Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Psychiatric API Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Psychiatric API Sales Quantity by Type (2021-2032)
  • 8.2 Europe Psychiatric API Sales Quantity by Application (2021-2032)
  • 8.3 Europe Psychiatric API Market Size by Country
    • 8.3.1 Europe Psychiatric API Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Psychiatric API Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Psychiatric API Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Psychiatric API Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Psychiatric API Market Size by Region
    • 9.3.1 Asia-Pacific Psychiatric API Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Psychiatric API Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Psychiatric API Sales Quantity by Type (2021-2032)
  • 10.2 South America Psychiatric API Sales Quantity by Application (2021-2032)
  • 10.3 South America Psychiatric API Market Size by Country
    • 10.3.1 South America Psychiatric API Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Psychiatric API Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Psychiatric API Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Psychiatric API Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Psychiatric API Market Size by Country
    • 11.3.1 Middle East & Africa Psychiatric API Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Psychiatric API Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Psychiatric API Market Drivers
  • 12.2 Psychiatric API Market Restraints
  • 12.3 Psychiatric API Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Psychiatric API and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Psychiatric API
  • 13.3 Psychiatric API Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Psychiatric API Typical Distributors
  • 14.3 Psychiatric API Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Psychiatric API market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Psychiatric API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Psychiatric API market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Psychiatric API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Psychiatric API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Psychiatric API market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Psychiatric API
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Psychiatric API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Eli Lilly, Salutas Pharma, Bora Pharmaceutical, Dr.Reddy's Laboratories, Germany Pharmaceutical, Hengrui Pharmaceuticals, Herui Pharmaceutical, Ren An Pharmaceutical, Yaopharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Psychiatric API market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Venlafaxine
    Duloxetine
    Olanzapine
    Paroxetine
    Others
    Market segment by Application
    Major Depressive Disorder
    Generalized Anxiety Disorder
    Fibromyalgia
    Schizophrenia
    Others
    Major players covered
    Pfizer
    Eli Lilly
    Salutas Pharma
    Bora Pharmaceutical
    Dr.Reddy's Laboratories
    Germany Pharmaceutical
    Hengrui Pharmaceuticals
    Herui Pharmaceutical
    Ren An Pharmaceutical
    Yaopharma
    Kanghong Pharmaceutical
    Brilliant Pharmaceutical
    Dongting Pharmaceutical
    Sichuan Chuanda West China Pharmaceutical
    Yangtze River Pharmaceutical
    Huahai Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Psychiatric API product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Psychiatric API, with price, sales quantity, revenue, and global market share of Psychiatric API from 2021 to 2026.
    Chapter 3, the Psychiatric API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Psychiatric API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Psychiatric API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Psychiatric API.
    Chapter 14 and 15, to describe Psychiatric API sales channel, distributors, customers, research findings and conclusion.

    Buy now